$TOVX
Theriva Biologics, Inc. Stock $tovx

$tovx Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415063126 Filed on November 05, 2015

Income Statement

Concept	2015 Q3	2014 Q4	2014 Q3
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.600M	$1.860M	$1.220M
YoY Change	31.15%	19.23%	-35.45%
% of Gross Profit
Research & Development	$10.05M	$5.240M	$3.693M
YoY Change	172.03%	93.36%	150.37%
% of Gross Profit
Depreciation & Amortization	$20.00K	$10.00K	$0.00
YoY Change		0.0%	-100.0%
% of Gross Profit
Operating Expenses	$11.65M	$7.100M	$4.911M
YoY Change	137.22%	66.28%	45.94%
Operating Profit	-$11.65M		-$4.911M
YoY Change	137.22%		45.94%
Interest Expense	$0.00	$0.00	$0.00
YoY Change			-100.0%
% of Operating Profit
Other Income/Expense, Net	$4.143M	$620.0K	$1.000K
YoY Change	414200.0%	1140.0%	-133.33%
Pretax Income	-$11.65M	-$7.101M	-$4.911M
YoY Change	137.22%	66.18%	45.94%
Income Tax		$0.00
% Of Pretax Income
Net Earnings	-$7.507M	-$6.480M	-$4.910M
YoY Change	52.89%	53.37%	45.78%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.08		-$0.08
Diluted Earnings Per Share	-$0.12	-$3.115M	-$0.08
COMMON SHARES
Basic Shares Outstanding	85.97M shares	72.51M shares	58.45M shares
Diluted Shares Outstanding	87.59M shares		58.45M shares

Balance Sheet

Concept	2015 Q3	2014 Q4	2014 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$31.81M	$17.53M	$3.290M
YoY Change	866.87%	19.82%	-36.12%
Cash & Equivalents	$31.81M	$17.53M	$3.286M
Short-Term Investments
Other Short-Term Assets	$10.33M	$1.548M	$1.382M
YoY Change	647.54%	-2.7%	-16.09%
Inventory
Prepaid Expenses	$227.0K	$253.0K	$193.0K
Receivables
Other Receivables
Total Short-Term Assets	$42.14M	$19.07M	$4.668M
YoY Change	802.68%	17.62%	-31.27%
LONG-TERM ASSETS
Property, Plant & Equipment	$483.0K	$65.00K	$67.00K
YoY Change	620.9%	75.68%	-57.32%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$10.00K	$10.00K	$10.00K
YoY Change	0.0%
Total Long-Term Assets	$497.0K	$71.00K	$73.00K
YoY Change	580.82%	73.17%	-54.66%
TOTAL ASSETS
Total Short-Term Assets	$42.14M	$19.07M	$4.668M
Total Long-Term Assets	$497.0K	$71.00K	$73.00K
Total Assets	$42.63M	$19.14M	$4.741M
YoY Change	799.26%	17.76%	-31.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$6.026M	$996.0K	$873.0K
YoY Change	590.26%	601.41%	49.49%
Accrued Expenses	$244.0K	$1.298M	$111.0K
YoY Change	119.82%	47.17%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$17.30M	$9.588M	$984.0K
YoY Change	1658.23%	833.59%	69.66%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$200.0K
YoY Change
Total Long-Term Liabilities	$200.0K	$0.00	$0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$17.30M	$9.588M	$984.0K
Total Long-Term Liabilities	$200.0K	$0.00	$0.00
Total Liabilities	$17.50M	$9.588M	$984.0K
YoY Change	1678.35%	833.59%	68.49%
SHAREHOLDERS EQUITY
Retained Earnings	-$133.8M	-$101.0M	-$94.56M
YoY Change	41.49%	24.35%	22.75%
Common Stock	$159.7M	$110.6M	$98.32M
YoY Change	62.39%	14.62%	17.88%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.87M	$9.556M	$3.757M
YoY Change
Total Liabilities & Shareholders Equity	$42.63M	$19.14M	$4.741M
YoY Change	799.26%	17.76%	-31.81%

Cashflow Statement

Concept	2015 Q3	2014 Q4	2014 Q3
OPERATING ACTIVITIES
Net Income	-$7.507M	-$6.480M	-$4.910M
YoY Change	52.89%	53.37%	45.78%
Depreciation, Depletion And Amortization	$20.00K	$10.00K	$0.00
YoY Change		0.0%	-100.0%
Cash From Operating Activities	-$15.21M	-$4.780M	-$4.530M
YoY Change	235.76%	77.04%	163.37%
INVESTING ACTIVITIES
Capital Expenditures	-$400.0K	-$10.00K	-$20.00K
YoY Change	1900.0%	0.0%	0.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	-$400.0K	-$10.00K	-$20.00K
YoY Change	1900.0%	0.0%	0.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	42.66M	19.03M	0.000
YoY Change		55.98%
NET CHANGE
Cash From Operating Activities	-15.21M	-4.780M	-4.530M
Cash From Investing Activities	-400.0K	-10.00K	-20.00K
Cash From Financing Activities	42.66M	19.03M	0.000
Net Change In Cash	27.05M	14.24M	-4.550M
YoY Change	-694.51%	50.05%	161.49%
FREE CASH FLOW
Cash From Operating Activities	-$15.21M	-$4.780M	-$4.530M
Capital Expenditures	-$400.0K	-$10.00K	-$20.00K
Free Cash Flow	-$14.81M	-$4.770M	-$4.510M
YoY Change	228.38%	77.32%	165.29%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Operating Expenses OperatingExpenses	13401000	USD
	us-gaap	Operating Expenses OperatingExpenses	29587000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-13401000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	5000	USD
CY2015Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	6026000	USD
CY2014Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	996000	USD
CY2014Q4	us-gaap	Minority Interest MinorityInterest	0	USD
CY2015Q3	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	25135000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4154000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5539000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9247000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	24048000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	97000	USD
	us-gaap	Profit Loss ProfitLoss	-33488000	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-733000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-209000	USD
CY2015Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	42634000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-29587000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2014Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-101042000	USD
CY2014Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	9556000	USD
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1548000	USD
	us-gaap	Profit Loss ProfitLoss	-13304000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3901000	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	19073000	USD
CY2015Q3	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	14000	USD
CY2015Q3	us-gaap	Minority Interest MinorityInterest	-733000	USD
CY2015Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	483000	USD
CY2015Q3	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	244000	USD
CY2015Q3	us-gaap	Common Stock Value CommonStockValue	91000	USD
CY2014Q4	syn	Deposits And Other Assets Noncurrent DepositsAndOtherAssetsNoncurrent	6000	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	72000	USD
CY2015Q3	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	159574000	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	110526000	USD
CY2015Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-133797000	USD
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	19144000	USD
CY2015Q3	us-gaap	Assets Assets	42634000	USD
CY2014Q4	us-gaap	Assets Assets	19144000	USD
CY2015Q3	us-gaap	Stockholders Equity StockholdersEquity	25868000	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	9556000	USD
CY2015Q3	syn	Warrant Liabilities WarrantLiabilities	10662000	USD
CY2014Q4	syn	Warrant Liabilities WarrantLiabilities	6756000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	65000	USD
CY2015Q3	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	314000	USD
CY2014Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1298000	USD
CY2014Q4	us-gaap	Accrued Employee Benefits Current AccruedEmployeeBenefitsCurrent	538000	USD
CY2015Q3	us-gaap	Liabilities Current LiabilitiesCurrent	17301000	USD
CY2015Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	31806000	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	9588000	USD
CY2015Q3	us-gaap	Liabilities Liabilities	17499000	USD
CY2014Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	17525000	USD
CY2014Q4	us-gaap	Liabilities Liabilities	9588000	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	95000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	1827000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2059000	USD
CY2015Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	10331000	USD
CY2015Q3	us-gaap	Assets Current AssetsCurrent	42137000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	3906000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13304000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-32755000	USD
CY2015Q3	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1604000	USD
CY2015Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	4143000	USD
CY2015Q3	us-gaap	Profit Loss ProfitLoss	-7507000	USD
CY2015Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-733000	USD
CY2015Q3	us-gaap	Net Income Loss NetIncomeLoss	-6774000	USD
CY2015Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-4141000	USD
	us-gaap	Depreciation Depreciation	13000	USD
	us-gaap	Depreciation Depreciation	39000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	8783000	USD
	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	2000	USD
	syn	Increase Decrease In Deposits And Other Assets IncreaseDecreaseInDepositsAndOtherAssets	8000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	731000	USD
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	5030000	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1054000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-11300000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-27920000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	43000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	457000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-43000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-457000	USD
	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	4000	USD
	syn	Proceeds From Issuance Of Common Stock For Stock Option And Warrants Exercises ProceedsFromIssuanceOfCommonStockForStockOptionAndWarrantsExercises	15000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	4000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	42658000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	-11339000	USD
	us-gaap	Cash Period Increase Decrease CashPeriodIncreaseDecrease	14281000	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14625000	USD
CY2014Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3286000	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Income Taxes Paid IncomeTaxesPaid	0	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	0	USD
	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	-1350000	USD
	syn	Stock Issued For Milestone Payments StockIssuedForMilestonePayments	0	USD
	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-774000	USD
CY2015Q3	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	30600000	USD
CY2014Q4	us-gaap	Money Market Funds At Carrying Value MoneyMarketFundsAtCarryingValue	13600000	USD
CY2015Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
CY2014Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1000	USD
CY2015Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-11650000	USD
CY2014Q3	us-gaap	Operating Expenses OperatingExpenses	4911000	USD
CY2014Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4911000	USD
CY2014Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	1000	USD
CY2014Q3	us-gaap	Profit Loss ProfitLoss	-4910000	USD
CY2014Q3	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	0	USD
CY2014Q3	us-gaap	Net Income Loss NetIncomeLoss	-4910000	USD
CY2014Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	0	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-224000	USD
CY2015Q3	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q3	syn	Accrued Vendor Payments AccruedVendorPayments	116000	USD
CY2015Q3	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	128000	USD
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q3	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	950000	USD
CY2014Q4	syn	Prepaid Expenses Research And Development PrepaidExpensesResearchAndDevelopment	1067000	USD
CY2015Q3	us-gaap	Prepaid Insurance PrepaidInsurance	65000	USD
CY2014Q4	us-gaap	Prepaid Insurance PrepaidInsurance	228000	USD
CY2015Q3	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	227000	USD
CY2014Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	253000	USD
CY2015Q3	us-gaap	Other Assets Current OtherAssetsCurrent	10331000	USD
CY2014Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1548000	USD
CY2015Q3	syn	Prepaid Clinical Research Organizations PrepaidClinicalResearchOrganizations	9089000	USD
CY2014Q4	syn	Prepaid Clinical Research Organizations PrepaidClinicalResearchOrganizations	0	USD
CY2015Q3	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	0	USD
CY2014Q4	syn	Accrued Manufacturing Costs AccruedManufacturingCosts	247000	USD
CY2014Q4	syn	Accrued Vendor Payments AccruedVendorPayments	176000	USD
CY2015Q3	syn	Accrued Milestone Payable AccruedMilestonePayable	0	USD
CY2014Q4	syn	Accrued Milestone Payable AccruedMilestonePayable	350000	USD
CY2014Q4	syn	Accrued Clinical Consulting Services AccruedClinicalConsultingServices	525000	USD
CY2015Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	72000	USD
CY2014Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	39000	USD
CY2015Q3	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4600000	USD
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	7029808	shares
CY2014	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	232619	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	454896	shares
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	1.75
CY2014	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	1.47
CY2014	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	1.88
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod	0	shares
	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriod	2448	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	63447	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0
	syn	Share Based Compensation Arrangement By Share Based Payment Award Other Than Options Exercises In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOtherThanOptionsExercisesInPeriodWeightedAverageGrantDateFairValue	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue	3.24
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	1632501	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7974794	shares
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	7908899	shares
CY2014Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.80
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.79
CY2013Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue	1.99
	dei	Document Type DocumentType	10-Q
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Period End Date DocumentPeriodEndDate	2015-09-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2015
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Entity Registrant Name EntityRegistrantName	Synthetic Biologics, Inc.
	dei	Entity Central Index Key EntityCentralIndexKey	0000894158
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Trading Symbol TradingSymbol	SYN
CY2015Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	90810086	shares
CY2015Q3	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	55000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	0	USD
CY2015Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	198000	USD
CY2014Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	0	USD
CY2015Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2014Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies	0	USD
CY2015Q3	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2015Q3	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q3	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q3	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2015Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	90891568	shares
CY2015Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	90810086	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	72594626	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	72513144	shares
	syn	Issue Of Stock For Exclusive Channel Collaboration Agreement IssueOfStockForExclusiveChannelCollaborationAgreement	-3000000	USD
	syn	Direct Offering Cost DirectOfferingCost	3357000	USD
	syn	Direct Offering Cost DirectOfferingCost	0	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	46000000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	253000	USD
	us-gaap	Increase Decrease In Deferred Compensation IncreaseDecreaseInDeferredCompensation	0	USD
CY2015Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	555000	USD
CY2014Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	104000	USD
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0	pure
CY2015Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0	pure
CY2015Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P0Y
CY2015Q3	syn	Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod	0	pure
CY2014Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2014Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2014Q3	syn	Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	syn	Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	syn	Share Based Compensation Arrangement By Share Based Payment Award Options Expected Forfeiture Rate In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpectedForfeitureRateInPeriod	0	pure
CY2015Q3	syn	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumption Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionExercisePrice	0
CY2015Q3	us-gaap	Equity Method Investment Ownership Percentage EquityMethodInvestmentOwnershipPercentage	0.885	pure
CY2015Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2014Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.42
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2015Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2014Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.08
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.42
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32755000	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-6774000	USD
CY2015Q3	us-gaap	Dilutive Securities DilutiveSecurities	-4141000	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
CY2015Q3	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
CY2015Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-10915000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-32755000	USD
CY2015Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	85974751	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	77300375	shares
CY2015Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	1610352	shares
CY2015Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	87585103	shares
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4910000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-13304000	USD
CY2014Q3	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
	us-gaap	Dilutive Securities DilutiveSecurities	0	USD
	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
CY2014Q3	syn	Dilutive Shares Related To Warrants DilutiveSharesRelatedToWarrants	0	USD
CY2014Q3	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-4910000	USD
	us-gaap	Net Income Loss Available To Common Stockholders Diluted NetIncomeLossAvailableToCommonStockholdersDiluted	-13304000	USD
CY2014Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58453528	shares
CY2014Q3	us-gaap	Incremental Common Shares Attributable To Call Options And Warrants IncrementalCommonSharesAttributableToCallOptionsAndWarrants	0	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58356025	shares
CY2014Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	58453528	shares
CY2015Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	77300375	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	58356025	shares

Files In Submission

Name	View Source	Status
0001144204-15-063126-index-headers.html	Edgar Link	pending
0001144204-15-063126-index.html	Edgar Link	pending
0001144204-15-063126.txt	Edgar Link	pending
0001144204-15-063126-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
syn-20150930.xml	Edgar Link	completed
syn-20150930.xsd	Edgar Link	pending
syn-20150930_cal.xml	Edgar Link	unprocessable
syn-20150930_def.xml	Edgar Link	unprocessable
syn-20150930_lab.xml	Edgar Link	unprocessable
syn-20150930_pre.xml	Edgar Link	unprocessable
v423087_10q.htm	Edgar Link	pending
v423087_ex10-1.htm	Edgar Link	pending
v423087_ex31-1.htm	Edgar Link	pending
v423087_ex31-2.htm	Edgar Link	pending
v423087_ex32-1.htm	Edgar Link	pending
v423087_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TOVX
Theriva Biologics, Inc. Stock $tovx

2015 Q3 Form 10-Q Financial Statement

#000114420415063126 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX Theriva Biologics, Inc. Stock $tovx

2015 Q3 Form 10-Q Financial Statement

#000114420415063126 Filed on November 05, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TOVX
Theriva Biologics, Inc. Stock $tovx